• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

    6/26/26 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email

    AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," featuring Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM).

    To hear the NetworkNewsAudio version, visit https://ibn.fm/H77V1

    To read the original editorial, visit: https://ibn.fm/wILk2

    [Multiple sclerosis] carries a heavy economic burden as well. The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is forecast to reach $38.62 billion by 2030, driven not by cures but by the sheer number of patients requiring lifelong management. That market reality underscores the scale of the unmet need. Patients need more than management; they need a therapy that can interrupt the disease.

    That is precisely what Quantum BioPharma is working to deliver. The company is developing Lucid-MS, a patented, first-in-class drug candidate unlike anything currently approved, which targets the myelin sheath itself, with the goal of preventing, stopping and even possibly allowing for reversing its degradation.

    About Quantum BioPharma Ltd.

    Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("unbuzzd") (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of unbuzzd at www.unbuzzd.com. The agreement with unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

    For further information, please visit the company’s website at www.QuantumBioPharma.com.

    NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

    About NetworkNewsAudio

    NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN ("InvestorBrandNetwork"), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

    For more information, visit: www.NetworkNewsAudio.com

    NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

    Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

    Corporate Communications

    IBN

    Austin, Texas

    www.InvestorBrandNetwork.com

    512.354.7000 Office

    Editor@InvestorBrandNetwork.com



    Primary Logo

    Get the next $QNTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    SEC Filings

    View All

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    6/2/26 11:50:53 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    6/2/26 7:40:04 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    5/18/26 6:00:09 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

    AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," featuring Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM). To hear the NetworkNewsAudio version, visit https://ibn.fm/H77V1 To read the original editorial, visit: https://ibn.fm/wILk2 [Multiple sclerosis] carries a heavy economic burden as well. The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is forecast to reach $38.62 billion by 2030, driven not by cures but by the sheer number of patients requiring lifelong management. That mar

    6/26/26 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

    NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, "The Quest to Repair What Multiple Sclerosis Takes Away,"  please visit: https://ibn.fm/PJ7yw Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million

    6/25/26 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Quest to Repair What Multiple Sclerosis Takes Away

    AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin

    6/24/26 8:30:00 AM ET
    $QNTM
    $NVS
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Financials

    Live finance-specific insights

    View All

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represen

    10/20/25 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

    TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date for the distribution of contingent value rights ("CVRs") to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press release dated June 13, 2025, to deliver a litigation-linked CVR to shareholders of record as of the record date. Each CVR will entitle the holder

    10/3/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Makes Strategic Investment in GameStop Corp.

    TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE:GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices. The Company has been at the forefront of fighting market corruption, as evidenced by

    7/22/25 7:00:00 AM ET
    $GME
    $QNTM
    Electronics Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

    TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026. First Quarter 2026 Financial Results As of March 31, 2026, the Company's combined cash and cash equivalents, and digital assets, totaled US$9.8 million, more than doubled from US$4.1 million as of December 31, 2025. Management confirms that current liquidity is sufficient to fund planned operations to approximately July 2027. As of the date of this press release, the fair market value of the Company's cryptocurrency portfolio is US$6.5 million, further st

    5/7/26 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

    TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reac

    4/22/26 9:16:08 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial evaluating Lucid-21-302 (Lucid-MS), an investigational therapy being developed to target demyelination in Multiple Sclerosis (MS). Dr. Salvatore Napoli, is an internationally recognized neurologist and key opinion leader in MS, with over 20 years of clinical and research experience. He is President and Medical Director

    3/26/26 8:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care